Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 6:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,006 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Adult Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects

NCT02415439
View directory record Official record
Conditions
Healthy
Interventions
VBP15, Placebo
Drug
Lead sponsor
ReveraGen BioPharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects

NCT00864500
View directory record Official record
Conditions
Healthy
Interventions
Clobetasol Propionate 0.05% lotion, single exposure, Clobex TM 0.05% Lotion, single exposure
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

NCT00490945
View directory record Official record
Conditions
Circadian Rhythm Sleep Disorders
Interventions
VEC-162
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
2
States / cities
Boston, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product

NCT03698305
View directory record Official record
Conditions
Healthy Subjects
Interventions
ASP5354, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Assessing Iron Sucrose or Venofer® in Healthy Adult Subjects

NCT04155814
View directory record Official record
Conditions
Bioequivalance
Interventions
Iron Sucrose Injection, Venofer Injection
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

NCT03874832
View directory record Official record
Conditions
Migraine With Aura, Migraine Without Aura, Migraine
Interventions
Dihydroergotamine
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Single Doses of IV Aerucin in Healthy Adults

NCT02486770
View directory record Official record
Conditions
Healthy
Interventions
Aerucin 2.0mg/kg, Aerucin 8.0mg/kg, Aerucin 20.0 mg/kg
Biological
Lead sponsor
Aridis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

NCT05116826
View directory record Official record
Conditions
Moderate Hepatic Impairment, Severe Hepatic Impairment, Liver Diseases
Interventions
Nitazoxanide
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers

NCT04536415
View directory record Official record
Conditions
Bioequivalence
Interventions
Oseltamivir Phosphate 75 mg capsules, Tamiflu capsules 75 mg
Drug
Lead sponsor
Austarpharma, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Protease Inhibitors

NCT00774735
View directory record Official record
Conditions
Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions
GSK1349572
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.

NCT00468689
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689 oral tablets (100 and 400 ng), Ketoconazole (NIZORAL) oral tablets (200 mg)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2008 · Synced Oct 7, 2026, 6:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug

NCT00382668
View directory record Official record
Conditions
Liver Diseases
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
4
States / cities
Miami, Florida • Miramar, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PK/PD and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adults

NCT02570074
View directory record Official record
Conditions
Healthy Subjects
Interventions
Fosfomycin
Drug
Lead sponsor
Vance Fowler, M.D.
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants

NCT04839809
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-92480, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants

NCT07050511
View directory record Official record
Conditions
SARS CoV-2
Interventions
GB-0669, Placebo
Drug
Lead sponsor
Generate Biomedicines
Industry
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

NCT03082235
View directory record Official record
Conditions
Healthy Participants
Interventions
E6742, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects

NCT05846009
View directory record Official record
Conditions
Osteochondrodysplasia
Interventions
SAR442501, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib

NCT05924152
View directory record Official record
Conditions
Healthy Adults
Interventions
Adagrasib, Eltrombopag + adagrasib
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55

NCT07019064
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Omaveloxolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects

NCT01104532
View directory record Official record
Conditions
Healthy, Pharmacokinetics of ASP1941
Interventions
ASP1941, sitagliptin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2010 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Adult Female Subjects

NCT05339633
View directory record Official record
Conditions
Mass Balance Recovery
Interventions
[14C]-D-0502
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

NCT04493671
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults

NCT02729467
View directory record Official record
Conditions
Healthy
Interventions
JNJ-53718678, Itraconazole, Rifampicin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 7, 2026, 6:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of VT-1598

NCT04208321
View directory record Official record
Conditions
Coccidioidomycosis
Interventions
Placebo, VT-1598
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 7, 2026, 6:50 PM EDT